Wynn Capital LLC Takes $1.36 Million Position in CVS Health Co. (NYSE:CVS)

Wynn Capital LLC acquired a new stake in CVS Health Co. (NYSE:CVS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,202 shares of the pharmacy operator’s stock, valued at approximately $1,358,000. CVS Health comprises 1.1% of Wynn Capital LLC’s holdings, making the stock its 29th largest position.

A number of other institutional investors have also modified their holdings of the company. Atticus Wealth Management LLC grew its holdings in CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 219 shares during the period. Cornerstone Planning Group LLC boosted its stake in shares of CVS Health by 111.5% in the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 243 shares during the period. ZRC Wealth Management LLC boosted its stake in shares of CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after purchasing an additional 400 shares during the period. Coston McIsaac & Partners boosted its stake in CVS Health by 42.6% during the 4th quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock valued at $42,000 after acquiring an additional 161 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in CVS Health in the fourth quarter worth about $50,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity

In related news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.24% of the company’s stock.

CVS Health Trading Down 1.1 %

CVS stock traded down $0.74 during midday trading on Wednesday, reaching $67.76. The company’s stock had a trading volume of 8,650,023 shares, compared to its average volume of 10,731,002. CVS Health Co. has a 52 week low of $64.41 and a 52 week high of $83.25. The stock has a market cap of $85.41 billion, a PE ratio of 10.52, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 0.77. The business’s 50-day simple moving average is $74.97 and its 200-day simple moving average is $73.76.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The company had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. During the same period last year, the firm posted $1.99 earnings per share. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, sell-side analysts expect that CVS Health Co. will post 8.31 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.93%. The ex-dividend date is Friday, April 19th. CVS Health’s dividend payout ratio (DPR) is presently 41.18%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CVS. Royal Bank of Canada decreased their target price on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research note on Thursday, February 8th. Leerink Partnrs restated an “outperform” rating on shares of CVS Health in a research report on Monday, February 26th. SVB Leerink began coverage on CVS Health in a research report on Monday, February 26th. They issued an “outperform” rating and a $88.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $87.00 target price on shares of CVS Health in a research report on Wednesday, April 10th. Finally, Barclays initiated coverage on CVS Health in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 target price for the company. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.